Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.59 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 13/20 | 0.45 |
| ▸ | HTR1D | P28221 | 13/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12343968 | 0.95 | CXCR4 (0.62) | CXCR4APOBEC3AAPOBEC3GHTR1AHTR1D | |
| SCHEMBL2492454 | 0.89 | CXCR4 (0.75) | CXCR4APOBEC3AAPOBEC3GHTR1AHTR1D | |
| SCHEMBL3792582 | 0.84 | CXCR4 (0.79) | CXCR4APOBEC3AAPOBEC3GHTR1AHTR1D | |
| SCHEMBL12344280 | 0.83 | CXCR4 (0.40) | CXCR4APOBEC3AAPOBEC3GHTR1AHTR1D | |
| SCHEMBL11133792 | 0.82 | CXCR4 (0.82) | CXCR4APOBEC3AAPOBEC3GHTR1AHTR1D | |
| SCHEMBL5831369 | 0.82 | CXCR4 (0.82) | CXCR4APOBEC3AAPOBEC3GHTR1AHTR1D | |
| SCHEMBL8431121 | 0.82 | CXCR4 (0.59) | CXCR4APOBEC3AAPOBEC3GHTR1AHTR1D | |
| SCHEMBL12341235 | 0.81 | CXCR4 (0.54) | CXCR4APOBEC3AAPOBEC3GHTR1AHTR1D | |
| SCHEMBL12603306 | 0.81 | — | — | |
| SCHEMBL8585904 | 0.81 | CXCR4 (0.62) | CXCR4APOBEC3AAPOBEC3GHTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221841-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-8580828-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-05-02 | — | — | US | disclosed |
| JP-2011206671-A | CARBON DIOXIDE ADSORBENT COMPOSED OF CYCLIC GUANIDINE COMPOUND, AND METHOD FOR PRODUCING CYCLIC GUANIDINE COMPOUND | YAMAGATA PROMOTIONAL ORGANIZATION FOR INDUSTRIAL TECHNOLOGY | 2011-10-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | CXCR4 3316/4885APOBEC3A 3608/4885APOBEC3G 3650/4885 |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | CXCR4 3557/4885APOBEC3A 3965/4885APOBEC3G 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.